Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease  by Gaedigk-Nitschko, K. et al.
FEBS 14983 FEBS Letters 357 (1995) 275 278 
Cleavage of recombinant and cell derived human immunodeficiency 
virus 1 (HI¥- 1) Nef protein by HIV- 1 protease 
K. Gaedigk-Nitschko, A. Sch6n, G. Wachinger, V. Erfle*, B. Kohleisen 
GSF-Forschungszentrum fiir Umwelt und Gesundheit, Institut fiir Molekulare Virologic, Neuherberg, Ingolstaedter Landst~ 1, 
85764 Oberschleissheim, Germany 
Received 19 October 1994; revised version received 1 December 1994 
Abstract Recombinant purified Nef protein of HIV-I, as well 
as Nef protein derived from extracts of permanently HIV-I in- 
fected glioblastoma cells and monocytes, are specifically cleaved 
by the HIV-1 protease. Nef cleavage products in cellular extracts 
treated with protease showed identical molecular weights as those 
obtained by digotion of purified Nef with recombinant HIV-I 
protease. Since cellular extracts were prepared by detergent and 
mechanical lysis it cannot be excluded that physiological cyto- 
plasmic conditions were altered. The lack of Nef cleavage by 
endogenous HIV-1 protease in infected cells might be due to low 
concentrations of viral protease and the presence of Gag precur- 
sor molecules as natural substrate. Using a panel of monoclonal 
antibodies two cleavage fragments of 19 kDa and 8 kDa were 
defined. The cleavage site was located by microsequencing be- 
tween amino acid 57 and 58 (AW*LEAQEEEEVGF). The con- 
served cleavage motif within HIV-I Nef suggests a potential 
biological function of Nef processing. 
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1. Introduction 
The Nef  protein is an accessory protein of the immunodefi- 
ciency viruses (HIV-1, HIV-2 and SIV). The functional role of 
HIV-1 Nef  for the viral life cycle is still unclear, as it is neither 
essential for virus replication or for the induction of cytopa- 
thic effects in vitro in permanent cell lines [1,2]. Contradictory 
observations were described concerning the putative negative 
regulatory function of HIV-1 Nef  and its properties as an GTP 
binding protein [1-4]. The involvement of Nef  protein in CD4 
down-regulation emphasizes its role in the infection and repli- 
cation process [5]. Immunofluorescence studies showed that 
Nef  is localized in the nucleus [6,7] associated with cellular 
membranes [8], and found in the cytoplasm [9,10] concentrated 
in the perinuclear region [6,7,11 ]. Therefore it could be possible 
that Nef  exerts several different regulatory functions during 
different stages of  infection. This might indicate that Nef  has 
to be post-translationally modified to exert its potential func- 
tions. An important modification is the myristoylation at the 
N-terminus of  Nef  [6,12]. Furthermore, phosphorylation 
[12,13] could contribute to multiple functional properties of 
Nef. As for the Gag precursor, a processing of Nef  by the 
HIV-1 protease has been predicted [14] and was shown for 
recombinant Nef  protein [15]. 
From these studies the question arises as to whether the 
cleavage vent might occur during natural infection in eukar- 
yotic cells. Such a kind of  Nef  processing could also alter or 
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activate as yet unknown functions in vivo. Here we confirm this 
observation in more detail and also show that this is true tor 
the Nef  processing in cellular extracts of persistently HIV-1- 
infected cells in the same manner as with recombinant purified 
Nef protein. 
2. Materials and methods 
2.1. HIV-1 Nef expression and purification 
The HIV LAV-1 Bru nef was cloned into the prokaryotic expression 
vector pTG959 (kindly provided by B. Guy from Transg6ne, Stras- 
bourg, France) and expressed in E. coli. Nef was solubilized from the 
bacterial lysate by addition of 8 M urea and 1% fl-mercaptoethanol. 
Purification of Nef protein was performed by affinity chromatography 
on heparin-Sepharose (Pharmacia, Freiburg, Germany) in a one-step 
purification procedure as described by Kohleisen et al. (submitted). Nef 
was eluted with 200 mM NaCI in a 10 mM sodium phosphate buffer, 
pH 7.5, and was directly used for cleavage xperiments. 
2.2. Proteolysis of HIV-1 Nef using recombinant HIV-1 protease 
Purified recombinant Nef protein was soluble in 10 mM sodium 
phosphate buffer, pH 7.5, with 200 mM NaC1. For enzymatic digestion, 
12 mM purified Nef and 2 mM recombinant purified HIV-1 protease 
(Bachem Bioscience Inc., Philadelphia, USA)were incubated at 37°C 
for 1 h. The inhibitor for HIV-1 protease, RO31-5989, was kindly 
provided by Roche Products Ltd., Welwyn Garden City, UK. 
For competition experiments equimolar amounts of p55 Gag protein 
(kindly provided by F. Bex, Department of Molecular Biology, Univer- 
sity of Brussels, Belgium) were added to Nef protein prior to enzymatic 
digestion. 
2.3. Cell lines and cell extraction 
Cellular extracts were prepared from persistently HIV-1 infected 
(TH4-7-5) and non-infected glioblastoma cells (85HG66) as described 
by Brack-Werner t al. [16]. A monocytic cell line (RC-2A) infected with 
HIV-1 derived from TH4-7-5 cells (RC-2ATH) was established as de- 
scribed by Kleinschmidt et al. (submitted). Cellular extracts were ob- 
tained by detergent lysis and high speed centrifugation as described 
previously [7]. 
2.4. SDS-PAGE and Western blot analysis 
Proteins were separated on linear 10-20% gels by SDS-PAGE and 
electroblotted onto nitrocellulose (NC BA83, Schleicher & Schuell, 
Dassel, Germany) according to [7]. 
Briefly, antibody dilutions were performed in 1% BSA in 50 mM Tris, 
pH 7.5, with 150 mM NaCI and 0.05% Tween 20. For detection of Nef, 
mouse monoclonal antibodies (mAbs) and a rabbit polyclonal Nef 
antiserum (27/89 4' [7]) were used. 
Mouse mAbs with mapped epitope specificities DI41 (aa 33 35), 
D 138 (aa 68 72), D212 (aa 51-71), D286 (aa 151-170), D5 (aa 198-204) 
were kindly provided by P. Wernet and L. Shi, Institut ftir Transfu- 
sionsmedizin, Universit~it Dfisseldorf, Germany. mAbs nef21 (aa 81- 
90) and nefl (aa 170-190) were a gift from R. v. Baehr, Charit6, 
Humboldt-Universit/it Berlin, Germany. Mab 3E6 (aa 168 175) and 
2H12 (aa 171-190) described by Ovod et al. [17] were kindly provided 
by K. Krohn, Department of Biomedical Science, University of Tam- 
pere, Finland. The purified mouse mAb NCRD 10/11 (Behring AG, 
Marburg, Germany) was used as first antibody for p55 Gag detection. 
As second antibody, an IgG-alkaline phosphatase conjugate 
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(Dianova, Hamburg, Germany) and as substrate Nitroblue tetrazolium 
and 5-bromo-4-chloro-3-indolylphosphate [18] w re used. The more 
sensitive ECL system was applied for detection of low protein concen- 
trations with a horseradish peroxidase (HRPO)-labelled IgG as second 
antibody according to the instructions of the manufacturer (Amer- 
sham-Buchler, Braunschweig, Germany). The nitrocellulose was ex- 
posed to an X-ray film (ECL hyperfilm, Amersham-Buchler, Braun- 
schweig, Germany) at -70°C. 
2.5. Microsequencing of the cleavage fragment 
Amino acid sequencing was independently performed by M. Eulitz, 
GSF, Institut fiir klinische Molekularbiologie und Tumorgenetik, and 
F. Lottspeich, TopLab, both Munich, Germany, using eleven cycles of 
Edman degradation after transfer of protein onto PVDF membrane 
(Bio-Rad, Munich, Germany). 
2.6. Sequence similarities 
HIV sequences are compared according to Myer's database [19]. It 
contains 24 members ofthe HIV-1 group (premature stopped sequences 
were rejected). Alignments and comparisons are performed with pro- 
grams from the GCG software package [20]: Pileup and Plotsimilarity. 
Plotsimilarity calculates the distances between the different sequences 
in a window (win), which has to be defined, win = 1 was chosen to 
compare the single amino acids at the cleavage site and win -- 7 to 
determine the global structure of the nef gene. 
3. Results and discussion 
3.1. Cleavage of Nef protein by HIV protease 
Cleavage of Nef by recombinant HIV-1 protease is shown in 
Fig. 1. Nef protein is rapidly and specifically digested into two 
fragments. Since mAb 2H12 was mapped to react with a pep- 
tide encompassing aa171 190 of Nef, only the larger Nef frag- 
ment with a molecular weight of approximately 19 kDa is 
detected. Eleven cycles of Edman degradation of this cleavage 
fragment revealed the amino acid sequence LEAQEEEEVGF, 
corresponding to the cleavage site between Tip 57 and Leu 58. 
First cleavage products are detected 5 min after incubation 
at 37°C at pH 7.5. The specificity of the cleavage was demon- 
strated by using 100 nM protease inhibitor RO31-5989. No 
cleavage products were observed in the presence of RO31-5989, 
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Fig. 1. Digestion of recombinant (rec) HIV-1 Nef protein with rec 
HIV-1 protease. E. coli expressed and purified Nef was digested with 
protease for various incubation times as indicated. As a control, Nef 
without protease was incubated for 60 min at 37°C. Proteins were 
separated on 10-20% SDS-polyacrylamide gels and electroblotted onto 
NC. For detection of the 19 kDa Nef fragment (arrow head), NC was 
probed with mAb 2H12, anti-mouse IgG-HRPO and ECL as substrate. 
The smaller 8kDa fragment isnot recognized since the epitope specific- 
ity of 2H 12 is located in the C-terminal part of Nef. Molecular weights 
(MW) of marker proteins are indicated on the right and Nef protein 
with an arrow. 
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Fig. 2. Analysis of cleavage fragments by mAbs. Digested recombinant 
Nef fragments were separated by SDS-PAGE. In Western blot analysis 
each lane was probed with a different mouse monoclonal ntibody. 
Epitopes recognized by mAbs are indicated. Arrow, Nef protein; 
arrowheads, 19 kDa and 8 kDa Nef fragments. 
an inhibitor designed to block the viral protease (data not 
shown). 
After 10 min of incubation a clear band representing the 
larger cleavage Nef fragment was observed. A longer incuba- 
tion time up to 60 min only led to a small increase in the amount 
of the cleaved product. This might be due to degradation of the 
viral protease during incubation or conformational inaccessi- 
bility of the cleavage site in multimer forms of Nef. No degra- 
dation of Nefis observed after 60 min at 37°C without protease 
(Fig. 1). 
3.2. Analysis of cleavage products by monoclonal ntibodies 
To demonstrate the presence of the smaller cleavage product 
and to analyze the reactivity of the two fragments, a panel of 
eight mAbs covering the Nef protein from aa 33 to 204 was 
applied. Mab D141 (aa 33-35) reacted exclusively with a 
smaller fragment of about 8 kDa whereas all other mAbs, 
except mAb D212, recognized the 19 kDa fragment. Mab D212 
reacted only with the uncleaved Nef protein since the epitope 
located at aa 51-71, which is recognized by this antibody, is 
destroyed by the cleavage vent (Fig. 2). 
3.3. Competition experiments with Gag protein p55 
To compare the efficiency of Nef cleavage with the cleavage 
of the natural substrate p55 Gag, competition experiments were 
performed. In the presence of equimolar amounts of purified 
Nef and p55 Gag proteins both substrates were cleaved by the 
protease (Fig. 3). Although the cleavage of Nef is less efficient 
in the presence of the Gag competitor, the 19 kDa Nef cleavage 
product is clearly detectable. This indicates that Nef might also 
be specifically processed in HIV-l-infected cells where large 
amounts of Gag and Gag-Pol precursor proteins are present. 
Furthermore, proteolytic fragmentation of cellular proteins 
[21], and especially components of the cytoskeleton [22-24], is 
described, demonstrating a broad spectrum of intracellular en- 
zymatic activity of the HIV-1 protease. 
3.4. Proteolytic fragmentation of Nef protein in cellular extracts 
To elucidate possible inhibitory effects and to assay the 
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cleavage fficiency of in vivo Nef synthesized in eukaryotic cells 
in its viral context we analyzed Nef cleavage in cellular extracts 
of persistently HIV-1-infected cells. We used the monocytic cell 
line RC-2AvH which supports active replication of the virus, 
and thus reasonable amounts of Nef and Gag-Pol proteins are 
present; as well as the astrocytic ell line TH4-7-5, repressing 
HIV-1 replication to a great extent in favor for an excess of Nef 
production. Addition of recombinant protease to cellular ex- 
tracts of TH4-7-5 and RC-2ATH led to a Nef cleavage pattern 
identical to digestion of recombinant Nef (Fig. 4). In extracts 
of non-infected cells no specific 19 kDa fragment appeared 
after protease treatment. Correct folding and post-translational 
modifications like phosphorylation and glycosylation of the 
Nef protein translated and processed uring a natural cycle of 
infection can be assumed. 
The physiological environment seems to permit cleavage of 
Nef synthesized and modified by the cell machinery. Such a 
truncated Nef fragment might exhibit modified or additional 
biological functions which could be important for viral replica- 
tion in vivo. 
3.5. Sequence analysis of the cleavage site 
Sequencing of the cleavage site also demonstrated, that pre- 
dictions of potential recognition sites for the viral protease 
based on the model of Poorman et al. [25] are not reliable. The 
two cleavage motifs in the Nef protein as hypothetically defined 
by this method are not processed by the viral protease. Chou 
[26] defined 21 possible cleavage sites for the HIV-1 protease. 
The motif selection JJJJJEJJ, where J stands for a random 
amino acid, appears rather simplified and it is unlikely that 19 
out of 21 sites, as predicted by this model, might be cryptic and 
therefore are not accessible to the protease. 
Sequence comparison of the cleavage motif by Plotsimilarity 
revealed a high conservation of the amino acids corrsponding 
to positions 56-65 in HIV-1 Bru (AW*LEAQEEEE) in most 
of the HIV-1 isolates in group A, B, D, and two out of four in 
group 0. The high conservation f this region in comparison to 
the N- and C-terminal parts of Nef indicates that it may have 
t / / /  
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Fig. 3. Purified p55 Gag as competitor. The cleavage of Nef, p55 Gag 
and Nef/p55 Gag was performed at 37°C for 30 min. After SDS-PAGE 
and electroblotting onto NC, Western blot analysis was performed with 
mAb 2H12 for Nef (a) and NCRD10/ll for p55 Gag (b). ECL system 
was used for visualization. Arrow on the right, p55 Gag; arrow on the 
left, Nef protein; arrowhead, 19 kDa Nef fragment. 
mab 2H12 [ 3D12 
Fig. 4. Digestion of eukaryotic-expressed N f in extracts of infected 
glioblastoma ceils and monocytes. Infected and non-infected cellular 
extracts were treated with recombinant protease. Western blot analysis 
was performed with mAb 2H 12 and 3D 12 and the ECL system. Recom- 
binant digested and undigested Nef were used as controls. Arrow, Nef 
protein; arrowhead, 19 kDa Nef fragment. 
a crucial biological function for Nef. The cleavage site is situ- 
ated to the left in a relatively constant part of the Nef protein, 
about 100 aa in length. 
A negative hydrophilic motif around the cleavage site of 
HIV-1 protease similar to that in the Nef protein can also be 
found in non-viral substrates like the Alzheimer amyloid pre- 
cursor (AAP). The similarity between the cleavage site de- 
scribed here and one of the cleavage sites [22] in the AAP is 
remarkable. In the region of the cleavage site six amino acids 
are identical: AW*LEAQEEEEVGF in Nef vs. KVVEVA*E- 
EEEVAE in the extracellular region of AAP. A similar motif 
(VFFEEQEDEIIGF) is found in the thyrotropin receptor [27], 
but cleavage by HIV-1 protease is not yet tested. 
Because of the presence of this sequence motif in cellular 
proteins one could assume that the cleavage of Nef by the 
HIV-1 protease is not only an event by chance but might have 
a biological function. The demonstration f the cleavage vent 
within HIV-l-infected cells remains to be elucidated. 
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